Company Overview
About Neurona Therapeutics
Neurona Therapeutics is a clinical-stage biotherapeutics company founded in 2013 and headquartered in San Francisco, California, that develops regenerative neural cell therapies for chronic neurological disorders. The company generates specific neuronal and glial cell types from human induced pluripotent stem cells (iPSCs) for transplantation into the nervous system, with the goal of repairing dysfunctional neural circuits that underlie conditions such as epilepsy, chronic pain, and other neurological diseases.
Business Model & Competitive Advantage
Neurona's lead program, NRTX-1001, consists of human interneuron progenitor cells derived from iPSCs that, once transplanted into the brain, mature into inhibitory interneurons — a cell type that is reduced or dysfunctional in drug-resistant focal epilepsy. In Phase 1/2 clinical trials, multiple patients treated with NRTX-1001 have shown dramatic reductions in seizure frequency, with some achieving complete seizure freedom — an outcome that is extremely rare in drug-resistant epilepsy. These early results have generated significant clinical excitement, as approximately one-third of epilepsy patients do not respond adequately to available medications.
Competitive Landscape 2025–2026
Neurona Therapeutics has raised over $115 million in total funding, including a $60 million Series C in 2024. Key investors include ARCH Venture Partners, F-Prime Capital, and GV. The company is also advancing NRTX-2001 for chronic pain and exploring additional neurological indications where interneuron transplantation may restore circuit balance. Neurona's approach is part of a broader emerging field of cell therapy for non-oncology indications, applying the manufacturing and cell engineering expertise developed in cancer cell therapy to neurological diseases.
Key Differentiators
Emerging Innovator
Neurona Therapeutics is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Similar Brands
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Compare Neurona Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Neurona Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Neurona Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Neurona Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →